The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
MDM2 Is a Negative Regulator of p21 , Independent of p53
Open accessAbstract
The MDM2 oncogene has both p53-dependent and p53-independent activities. We have previously reported that antisense MDM2 inhibitors have significant anti-tumor activity in multiple human cancer models with various p53 statuses (Zhang, Z., Li, M., Wang, H., Agrawal, S., and Zhang, R. (2003) Proc. Natl. Acad. Sci. U. S. A. 100, 11636-11641). We have also provided evidence that MDM2 has a direct role in the regulation of p21, a cyclin-dependent kinase inhibitor. Here we provide evidence supporting functional interaction between MDM2 and p21 in vitro and in vivo. The inhibition of MDM2 with anti-MDM2 antisense oligonucleotide or Short Interference RNA targeting MDM2 significantly elevated p21 protein levels in PC3 cells (p53 null). In contrast, overexpression of MDM2 diminished the p21 level in the same cells by shortening the p21 half-life, an effect reversed by MDM2 antisense inhibition. MDM2 facilitates p21 degradation independent of ubiquitination and the E3 ligase function of MDM2. Instead, MDM2 promotes p21 degradation by facilitating binding of p21 with the proteasomal C8 subunit. The physical interaction between p21 and MDM2 was demonstrated both in vitro and in vivo with the binding region in amino acids 180-298 of the MDM2 protein. In summary, we provide evidence supporting a physical interaction between MDM2 and p21. We also demonstrate that, by reducing p21 protein stability via proteasome-mediated degradation, MDM2 functions as a negative regulator of p21, an effect independent of both p53 and ubiquitination.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506
Pomerantz, J., Schreiber-Agus, N., Liégeois, N. J., Silverman, A., Alland, L., Chin, L., Potes, J., Chen, K., Orlow, I., Lee, H.-W., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81400-2 · Cited by 1,521
Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53
Oliner, J. D., Pietenpol, J. A., Thiagalingam, S., Gyuris, J., Kinzler, K. W., & Vogelstein, B. (1993) · Nature · doi:10.1038/362857a0 · Cited by 1,451
Mdm2 Is a RING Finger-dependent Ubiquitin Protein Ligase for Itself and p53
Fang, S., Jensen, J. P., Ludwig, R. L., Vousden, K. H., & Weissman, A. M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.12.8945 · Cited by 1,044
Transcriptional Regulation of the p21(WAF1/CIP1)Gene
Gartel, A. L., & Tyner, A. L. (1999) · Experimental Cell Research · doi:10.1006/excr.1998.4319 · Cited by 664
Kriwacki, R. W., Hengst, L., Tennant, L., Reed, S. I., & Wright, P. E. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11504 · Cited by 575
Role of the SCFSkp2 Ubiquitin Ligase in the Degradation of p21Cip1 in S Phase
Bornstein, G., Bloom, J., Sitry-Shevah, D., Nakayama, K., Pagano, M., & Hershko, A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301774200 · Cited by 494
Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein
Martin, K., Trouche, D., Hagemeier, C., Sorensen, T. S., La Thangue, N. B., & Kouzarides, T. (1995) · Nature · doi:10.1038/375691a0 · Cited by 454
Lin, H.-K. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf406 · Cited by 450
p300/MDM2 complexes participate in MDM2-mediated p53 degradation
Grossman, S. R., Perez, M., Kung, A. L., Joseph, M., Mansur, C., Xiao, Z.-X., Kumar, S., Howley, P. M., & Livingston, D. M. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80140-9 · Cited by 414
Proteasomal Turnover of p21Cip1 Does Not Require p21Cip1 Ubiquitination
Sheaff, R. J., Singer, J. D., Swanger, J., Smitherman, M., Roberts, J. M., & Clurman, B. E. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)80435-9 · Cited by 382
Proteasome-Mediated Degradation of p21 via N-Terminal Ubiquitinylation
Bloom, J., Amador, V., Bartolini, F., DeMartino, G., & Pagano, M. (2003) · Cell · doi:10.1016/s0092-8674(03)00755-4 · Cited by 322
The ribosomal L5 protein is associated with mdm-2 and mdm-2-p53 complexes.
Marechal, V, Elenbaas, B., Piette, J., Nicolas, J. C., & Levine, A. J. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.11.7414 · Cited by 318
Ubiquitination of p53 and p21 Is Differentially Affected by Ionizing and UV Radiation
Maki, C. G., & Howley, P. M. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.1.355 · Cited by 308
Touitou, R. (2001) · The EMBO Journal · doi:10.1093/emboj/20.10.2367 · Cited by 236
Mdm2 binds p73α without targeting degradation
Bálint, E., Bates, S., & Vousden, K. H. (1999) · Oncogene · doi:10.1038/sj.onc.1202781 · Cited by 212
Zhang, Z., Li, M., Wang, H., Agrawal, S., & Zhang, R. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1934692100 · Cited by 192
Self-citationSynergistic activation of p53 by inhibition of MDM2 expression and DNA damage
Chen, L., Agrawal, S., Zhou, W., Zhang, R., & Chen, J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.1.195 · Cited by 159
Self-citationSignal Transduction Pathways of Taxanes-Induced Apoptosis
Ganansia, V., Bischoff, P. L., Bergerat, J., et al. (2003) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1568011033482422 · Cited by 128
Wang, H., Nan, L., Yu, D. S., Agrawal, S., & Zhang, R. (2001) · PubMed · Cited by 123
Self-citationMDM2 Oncogene as a Novel Target for Human Cancer Therapy
Zhang, R., & Wang, H. (2000) · Current Pharmaceutical Design · doi:10.2174/1381612003400911 · Cited by 113
Self-citationWang, H., Yu, D., Agrawal, S., & Zhang, R. (2003) · The Prostate · doi:10.1002/pros.10187 · Cited by 78
Self-citationVitamin D Analogues Increase p53, p21, and Apoptosis in a Xenograft Model of Human Retinoblastoma
Audo, I. S., Darjatmoko, S. R., Schlamp, C. L., Lokken, J. M., Lindstrom, M. J., Albert, D. M., & Nickells, R. W. (2003) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.02-1198 · Cited by 78
Gerards, W. L. H., JONG, W. W. D., BLOEMENDAL, H., & Boelens, W. C. (1998) · Journal of Molecular Biology · doi:10.1006/jmbi.1997.1429 · Cited by 61
Wang, H., Nan, L., Yu, D. S., Lindsey, J. R., Agrawal, S., & Zhang, R. (2002) · Molecular Medicine · doi:10.1007/bf03402011 · Cited by 51
Self-citationYang, H.-L., Pan, J.-X., Sun, L., & Yeung, S. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020992 · Cited by 49
Gotoh, A., Shirakawa, T., Wada, Y., Fujisawa, M., Okada, H., Kamidono, S., & Hamada, K. (2003) · British Journal of Urology · doi:10.1046/j.1464-410x.2003.04318.x · Cited by 16
Cited by
Drug discovery in the ubiquitin–proteasome system
Nalepa, G., Rolfe, M., & Harper, J. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2056 · Cited by 608
Chauhan, D., Tian, Z., Nicholson, B., Kumar, K. G. S., Zhou, B., Carrasco, R., McDermott, J. L., Leach, C. A., Fulcinniti, M., Kodrasov, M. P., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.08.007 · Cited by 589
Ubiquitin-like protein conjugation and the ubiquitin–proteasome system as drug targets
Bedford, L., Lowe, J., Dick, L. R., Mayer, R. J., & Brownell, J. E. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3321 · Cited by 563
MDM2 inhibitors for cancer therapy
Vassilev, L. T. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.11.002 · Cited by 532
Structural disorder throws new light on moonlighting
Tompa, P., Szász, C., & Buday, L. (2005) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2005.07.008 · Cited by 473
Metadata
- Authors
- Zhang, Z., Wang, H., Li, M., Agrawal, S., Chen, X., & Zhang, R.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2004-04
- Volume
- 279
- Issue
- 16
- Pages
- 16000-16006
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W1965531638
- Cited by
- 252
- References
- 28
- FWCI
- 8.67
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.